Skin Pencil
Composition:
One gram contains: Active ingredient Aciclovir 50 mg Excipients: butyl-hydroxytoluene For the full list of excipients, see section 6.1
Excipients
Castor oil, semi-synthetic glycerides, carnauba wax, white paraffin, beeswax, octyldodecanol, vanilla flavor, butyl-hydroxytoluene.
Therapeutic indications
EFRIVIRALLABIALE is indicated for the treatment of herpes simplex virus infections of the lips (recurrent herpes labialis) in adults and adolescents (over 12 years of age).
Contraindications
Patients with Hypersensitivity to aciclovir, valaciclovir, or to any of the excipients. Children under 12 years of age.
Dosage
Adults and adolescents (over 12 years of age) EFRIVIRALLABIALE should be applied 5 times a day at approximately 4-hour intervals, omitting the nighttime application. EFRIVIRALLABIALE should be applied to the lesions or areas where they are developing, as early as possible after the onset of the infection. It is particularly important to start treatment of recurrent episodes during the prodrome phase or at the first appearance of the lesions. Treatment should continue for at least 5 days and up to a maximum of 10 if healing has not occurred. The medicine should be applied directly to the lesions without using contact with the hands; patients must, however, wash their hands after application; Avoid unnecessary rubbing of the lesions or touching them with a towel to prevent worsening or transmission of the infection. The medicine is for personal use only; therefore, once opened, it must be used by the same patient for the entire shelf life of the medicine and must not be shared with other patients. Children under 12 years of age: The safety and efficacy of EFRIVIRALLABIALE have not been studied in patients under 12 years of age.
Warnings and precautions
EFRIVIRALLABIALE should only be used for cold sores on the lips. Application to the mucous membranes of the mouth or nose is not recommended. The medicine should not be used to treat genital herpes. Particular care must be taken to avoid accidental application to the eyes. Use of the product, especially if prolonged, may give rise to sensitization phenomena; if this occurs, treatment should be discontinued. No phenomena of habituation or dependence on the drug have been reported. It is recommended that people with particularly severe forms of recurrent cold sores consult their doctor. It is recommended that those suffering from cold sores avoid transmitting the virus, especially when active lesions are present. The safety and efficacy of EFRIVIRALLABIALE have not been studied in patients with an impaired immune system, therefore the use of EFRIVIRALLABIALE is not recommended in severely immunocompromised patients (AIDS patients or patients with bone marrow transplants). In these patients, the administration of aciclovir in oral formulations should be considered. Furthermore, it is recommended that these patients consult their doctor regarding the treatment of any infection. Important information about some of the excipients of EFRIVIRALLABIALE: The butylhydroxytoluene contained in the medicine can cause allergic reactions (possibly delayed). It can cause serious eye irritation. cause local skin reactions (e.g. contact dermatitis) or irritation of the eyes and mucous membranes.
Interactions
Other types of dermatological products (such as cosmetics, sunscreens, cocoa butter) or drugs that treat herpes should not be applied at the same time as EFRIVIRALLABIALE.
Undesirable effects
The following convention has been used for the classification of adverse reactions in terms of frequency: very common
Product Code:FRCM046058
Richiedi info sul prodotto
